文献速递儿童感染儿童呼吸儿童神经与发育行为

儿童流感相关死亡的临床特征与危险因素分析

[Analysis of clinical characteristics and risk factors of influenza-related deaths in children].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2020-01-01

该研究回顾性分析深圳市儿童医院PICU 2009年1月至2019年12月31例流感相关死亡患儿与188例存活重症流感患儿的临床资料,发现继发感染、首剂NAI>48 h、并发ARDS及IAE是重症流感患儿死亡的危险因素。

要点

  • 死亡组患儿感染前1年内均未接种流感疫苗。
  • 继发感染、首剂NAI>48 h、并发ARDS及IAE是死亡危险因素。
  • 死亡组继发感染率41.9%高于存活组20.2%(P=0.008)。

核心结论

  • 流感可导致多系统并发症,尤其是肺部感染及流感相关脑病(IAE)。
  • 识别并积极控制继发感染和并发症、及时给予神经氨酸酶抑制剂(NAI)能够提高重症流感患儿救治成功率。

研究设计与样本

  • 回顾性分析深圳市儿童医院PICU 2009年1月至2019年12月住院的31例流感相关死亡病例(死亡组)的临床资料。
  • 以同期PICU住院救治存活的188例重症流感患儿为存活组。
  • 采用两独立样本t检验、Mann-Whitney U检验或χ²检验对比分析两组资料,死亡危险因素采用多因素Logistic回归分析。

主要发现

  • 共219例重症流感患儿,死亡31例,男19例、女12例,年龄(4.2±3.3)岁,甲型流感病毒感染29例、乙型流感病毒感染2例,冬春季多见(23例),8例有基础疾病。
  • 存活188例,男138例、女50例,年龄(3.4±2.7)岁,甲型流感病毒感染151例,乙型流感病毒感染37例,20例有基础疾病。
  • 死亡组31例患儿临床表现发热31例、咳嗽21例、惊厥17例;IAE 17例;肺炎17例,塑型性支气管炎1例,气漏综合征3例,ARDS 8例;多器官功能障碍综合征24例;继发感染13例,革兰阳性球菌9例。
  • 死亡组31例均使用NAI抗病毒治疗,24例在发热48 h后首次用药;23例死于流感并发症,4例死于基础疾病,4例死于继发感染。
  • 与存活组比较,死亡组多有基础疾病[25.8%(8/31)比10.6%(20/188),χ²=4.215,P=0.040],继发感染发生率高[41.9%(13/31)比20.2%(38/188),χ²=7.029,P=0.008],应用NAI时间晚[77.4%(24/31)比53.7%(101/188),χ²=6.099,P=0.014]。

关键数值与推荐

  • Logistic回归分析显示继发感染、首剂NAI>48 h、并发ARDS及IAE是重症流感患儿死亡的危险因素(P均<0.05)。

临床怎么用

  • 临床应识别并积极控制重症流感患儿的继发感染和并发症。
  • 及时给予NAI抗病毒治疗以提高救治成功率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the clinical characteristics and risk factors of influenza-related deaths in children and to raise awareness of the disease among clinicians. Methods: Clinical data of 31 influenza-related deaths hospitalized in Pediatric Intensive Care Unit (PICU) of Shenzhen Children's Hospital from January 2009 to December 2019 (death group) were retrospectively analyzed. A control group enrolled 188 patients with severe influenza who were successfully cured and hospitalized in PICU at the same time. Independent Student's t test, Mann-Whitney U test and chi square test were used to compare the general conditions, clinical manifestations, laboratory tests and antiviral therapy between two groups. Risk factors of mortality in children with severe influenza were identified by multivariate Logistic regression. Results: In a total of 219 cases with severe influenza, 31 cases progressed to influenza-related deaths, 19 males and 12 females, with age of (4.2±3.3) years; 29 cases had influenza A virus infection and 2 cases had influenza B virus infection. Deaths occurred more in winter and spring (23/31). Eight patients had underlying diseases. In 188 patients who were successfully cured, 138 were males and 50 females, with an average age of (3.4±2.7)years. There were 151 patients with influenza A virus infection, and 37 patients with influenza B virus infection. Twenty patients underlying diseases. None of the patients in the death group has received the influenza vaccine within 1 year before infection. Common symptoms were fever (n=31), cough (n=21), and seizures (n=17) in the death group. The complications were influenza associated encephalopathy (IAE) (n=17), pneumonia (n=17), plastic bronchitis (n=1), air leak syndrome (n=3), acute respiratory distress syndrome (ARDS) (n=8), and multiple organ dysfunction syndrome (n=24). In the death group, 13 patients had secondary infections, of whom 9 cases had gram-positive Cocci infection. Complete blood count of the patients showed that white blood cells count increased in 15 cases and the lymphocyte count decreased in 13 cases. Meanwhile, high sensitivity C-reactive protein increased in 18 patients. All the 31 patients in the death group were treated with neuraminidase inhibitors for antiviral therapy, of whom 24 cases received the first dose 48 h after fever (late neuraminidase inhibitor (NAI) treatment). The causes of death in 31 patients were further analyzed, including 23 cases died of influenza complications, 4 cases died of underlying diseases and 4 cases died of secondary infections. Compared with the control group, the death group had more underlying diseases (25.8% (8/31) vs. 10.6% (20/188), χ²=4.215, P=0.040), higher incidence of secondary infection (41.9% (13/31) vs. 20.2% (38/188), χ²=7.029, P=0.008), and more late NAI treatment (77.4% (24/31) vs. 53.7% (101/188), χ²=6.099, P=0.014). Logistic regression analysis showed that secondary infection, late NAI treatment, complicated with ARDS and IAE were risk factors for death of patients with severe influenza (all P<0.05). Conclusions: Influenza can cause multi-system disorder, especially lung infections and IAE. It can improve the success rate of treatment for children with severe influenza, identification and early treatment of secondary infection and complications, and timely administration of NAI treatment. 目的: 探讨儿童流行性感冒(流感)相关死亡患儿的临床特点和高危因素,提高临床医生的认识。 方法: 回顾性分析深圳市儿童医院儿童重症监护病房(PICU)2009年1月至2019年12月住院的31例流感相关死亡病例(死亡组)的临床资料。以同期PICU住院救治存活的188例重症流感患儿为存活组。采用两独立样本t检验,Mann-Whitney U检验或χ²检验对比分析两组患儿的一般情况、临床表现、实验室检查及抗病毒治疗等资料。重症流感患儿死亡危险因素采用多因素Logistic回归分析。 结果: 共219例重症流感患儿,死亡31例,男19例、女12例,年龄(4.2±3.3)岁,甲型流感病毒感染29例、乙型流感病毒感染2例,冬春季多见(23例),8例有基础疾病。救治存活188例,男138例、女50例,年龄(3.4±2.7)岁,甲型流感病毒感染151例,乙型流感病毒感染37例,20例有基础疾病。死亡组患儿感染前1年内均未接种流感疫苗。死亡组31例患儿临床表现发热31例、咳嗽21例、惊厥17例。流感相关脑病(IAE)17例;肺炎17例,塑型性支气管炎1例,3例气漏综合征,8例进展为急性呼吸窘迫综合征(ARDS);24例发生多器官功能障碍综合征;13例发生继发感染,革兰阳性球菌9例;血常规15例白细胞计数升高,13例淋巴细胞计数降低,18例超敏C反应蛋白(hsCRP)升高。死亡组31例患儿均使用神经氨酸酶抑制剂抗病毒治疗,24例在发热48 h后首次用药;23例死于流感并发症,4例死于基础疾病,4例死于继发感染。与存活组比较,死亡组患儿多有基础疾病[25.8%(8/31)比10.6%(20/188),χ²=4.215,P=0.040],继发感染发生率高[41.9%(13/31)比20.2%(38/188),χ²=7.029,P=0.008],应用神经氨酸酶抑制剂(NAI)时间晚[77.4%(24/31)比53.7%(101/188),χ²=6.099,P=0.014]。Logistic回归分析显示继发感染、首剂NAI>48 h、并发ARDS及IAE是重症流感患儿死亡的危险因素(P均<0.05)。 结论: 流感可导致多系统并发症,尤其是肺部感染及IAE。识别并积极控制继发感染和并发症,及时给予NAI能够提高重症流感患儿救治成功率。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yu Q, Zhou H, Zhang T, et al. [Analysis of clinical characteristics and risk factors of influenza-related deaths in children]. Zhonghua Er Ke Za Zhi. 2020. PMID: 33120463. doi:10.3760/cma.j.cn112140-20200526-00546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。